Healthcare entity
acquisition is the sole category represented across all 1 tracked stories. Of the tracked stories, 1 of 1 also mention AstraZeneca, the most common co-covered peer. The tracked stories average 2 original sources each. Opdivo appears in 1 tracked Healthcare story from August 2, 2026.
Last mentioned: Aug 2, 2026
Entity pulse
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
acquisition is the sole category represented across all 1 tracked stories. Of the tracked stories, 1 of 1 also mention AstraZeneca, the most common co-covered peer. The tracked stories average 2 original sources each. Opdivo appears in 1 tracked Healthcare story from August 2, 2026.
Computed from the 1 stories linked to this entity, with beat comparisons drawn from all 10 Healthcare stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering Opdivo. Shared-story counts are live from our verified record — not editorial picks.
A potential $400 billion merger between AstraZeneca and Bristol Myers Squibb could reshape oncology competition, with implications for drug costs, patient access, and payer negotiations. The combined portfolio would dominate key cancer markets.
Opdivo is linked from 1 story on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.
